Abstract
Increased activity of plasma membrane K+ channels, leading to decreased cytoplasmic K+ concentrations, occurs during neuronal cell death. In the present study, we showed that the neurotoxic beta-amyloid peptide Abeta(25-35) caused a dose-dependent (0.1-10 microm) and time-dependent (> 12 h) enhancement of both inactivating and non-inactivating components of voltage-dependent K+ (VGK) currents in nerve growth factor-differentiated rat phaeochromocytoma (PC-12) cells and primary rat hippocampal neurones. Similar effects were exerted by Abeta(1-42), but not by the non-neurotoxic Abeta(35-25) peptide. Abeta(25-35) and Abeta(1-42) caused an early (15-20 min) increase in intracellular Ca(2+) concentration. This led to an increased production of reactive oxygen species (ROS), which peaked at 3 h and lasted for 24 h; ROS production seemed to trigger the VGK current increase as vitamin E (50 microm) blocked both the Abeta(25-35)- and Abeta(1-42)-induced ROS increase and VGK current enhancement. Inhibition of protein synthesis (cycloheximide, 1 microg/mL) and transcription (actinomycin D, 50 ng/mL) blocked Abeta(25-35)-induced VGK current enhancement, suggesting that this potentiation is mediated by transcriptional activation induced by ROS. Interestingly, the specific nuclear factor-kappaB inhibitor SN-50 (5 microm), but not its inactive analogue SN-50M (5 microm), fully counteracted Abeta(1-42)- or Abeta(25-35)-induced enhancement of VGK currents, providing evidence for a role of this family of transcription factors in regulating neuronal K+ channel function during exposure to Abeta.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
4-Aminopyridine / pharmacology
-
Actin Cytoskeleton / metabolism
-
Amyloid beta-Peptides / chemistry
-
Amyloid beta-Peptides / toxicity*
-
Animals
-
Blotting, Western / methods
-
Calcium / metabolism
-
Cell Differentiation / drug effects
-
Cells, Cultured
-
Charybdotoxin / pharmacology
-
Chelating Agents / pharmacology
-
Cnidarian Venoms
-
Dactinomycin / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Egtazic Acid / pharmacology
-
Electric Stimulation / methods
-
Embryo, Mammalian
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / pharmacology
-
GAP-43 Protein / metabolism
-
Hippocampus / cytology*
-
Membrane Potentials / drug effects
-
Membrane Potentials / physiology
-
Membrane Potentials / radiation effects
-
NF-kappa B / metabolism*
-
Nerve Growth Factor / pharmacology
-
Neurons / drug effects*
-
Neurons / physiology
-
PC12 Cells / cytology
-
PC12 Cells / drug effects
-
Patch-Clamp Techniques / methods
-
Peptide Fragments / toxicity
-
Peptides / pharmacology
-
Potassium Channel Blockers / pharmacology
-
Potassium Channels, Voltage-Gated / physiology*
-
Protein Synthesis Inhibitors / pharmacology
-
Rats
-
Reactive Oxygen Species / metabolism*
-
Tetraethylammonium / pharmacology
-
Time Factors
-
Vitamin A / pharmacology
Substances
-
Amyloid beta-Peptides
-
BDS-I antiviral protein, Anemonia sulcata
-
Chelating Agents
-
Cnidarian Venoms
-
Enzyme Inhibitors
-
GAP-43 Protein
-
NF-kappa B
-
Peptide Fragments
-
Peptides
-
Potassium Channel Blockers
-
Potassium Channels, Voltage-Gated
-
Protein Synthesis Inhibitors
-
Reactive Oxygen Species
-
SN50 peptide
-
Vitamin A
-
Charybdotoxin
-
Dactinomycin
-
Egtazic Acid
-
Tetraethylammonium
-
Nerve Growth Factor
-
4-Aminopyridine
-
Calcium